Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis in the U.S.

[1]  A. Facciorusso,et al.  Utilization of Hepatocellular Carcinoma Surveillance Programs in Patients With Cirrhosis , 2021, Journal of clinical gastroenterology.

[2]  Young Don Kim,et al.  Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study , 2020, Journal of gastroenterology and hepatology.

[3]  Y. Kim,et al.  Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. , 2020 .

[4]  J. Marrero,et al.  Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  A. Lok,et al.  The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers , 2020, Hepatology.

[6]  J. Byun,et al.  Non-enhanced Magnetic Resonance Imaging as a Surveillance Tool for Hepatocellular Carcinoma: Comparison with Ultrasound. , 2019, Journal of hepatology.

[7]  C. Santhakumar,et al.  HCC screening: assessment of an abbreviated non-contrast MRI protocol , 2019, European Radiology Experimental.

[8]  Kathleen F. Kerr,et al.  Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. , 2019, Journal of hepatology.

[9]  J. An,et al.  Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis , 2019, Hepatology.

[10]  A. Singal,et al.  Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  K. Kerr,et al.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.

[12]  M. Khalili,et al.  Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population , 2018, Hepatology communications.

[13]  J. Roberts,et al.  Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[15]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[16]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[17]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[18]  B. Taouli,et al.  Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis , 2017, Clinical and translational gastroenterology.

[19]  J. Byun,et al.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma , 2017, JAMA oncology.

[20]  M. Pedrosa,et al.  Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis , 2017, Hepatology.

[21]  Jasmin A. Tiro,et al.  Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. , 2017, Gastroenterology.

[22]  Jasmin A. Tiro,et al.  Patient‐reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis , 2016, Hepatology.

[23]  C. Lu,et al.  Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis , 2016, The American Journal of Gastroenterology.

[24]  Jasmin A. Tiro,et al.  Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  G. Ioannou,et al.  Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  Jennifer Marmo,et al.  Predicting substance-abuse treatment providers' communication with clients about medication assisted treatment: a test of the theories of reasoned action and planned behavior. , 2014, Journal of substance abuse treatment.

[27]  Y. Kono,et al.  Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA , 2014, Digestive Diseases and Sciences.

[28]  P. Thuras,et al.  Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study , 2013, Alimentary pharmacology & therapeutics.

[29]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[30]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[31]  S. Millstein.  Utility of the theories of reasoned action and planned behavior for predicting physician behavior: a prospective analysis. , 1996, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.